Crossmark

Epidemiology of diabetes and diabetic complications in China

Crossref DOI link: https://doi.org/10.1007/s00125-018-4557-7

Published Online: 2018-02-01

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ma, Ronald C. W.
Funding

Funding for this research was provided by:

Health and Medical Research Fund (13140761)

Research Grants Council, University Grants Committee (Theme-based Research Scheme (T12-402/13N))

The Chinese University of Hong Kong (Vice-Chancellor One-off Discretionary Fund)
License Information

Text and Data Mining valid from 2018-02-01
More Information

Article History

Received: 6 September 2017

Accepted: 21 November 2017

First Online: 1 February 2018

Change Date: 18 April 2018

Change Type: Correction

Change Details: Unfortunately, the reference given in the legend to Fig. 2 was incorrect. The legend should have stated that Fig. 2 was drawn based on data from reference [49].

Duality of interest

: RCWM received research funding from AstraZeneca, Bayer, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer and Takeda for conducting clinical trials, speaker honorarium or consultancy in advisory boards. All proceeds have been donated to the Chinese University of Hong Kong to support diabetes research.